The net present value rule is the idea that company managers and investors should only invest in projects or engage in transactions that have a positive net present value (NPV). They should avoid investing in projects that have a negative net present value. However, how does these criteria fit for investing in new sector projects - such as biotech, FINTECH, or AI type projects where future cash flows are hard to determine?